LORI EDWARDS: Open Payments
NPI 1467983601 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,748 in 137 payments from 17 companies in 2025. Trend: 2023 $1,286 · 2024 $2,505 · 2025 $2,748
Food & beverage: $2,748
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $807 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $350 |
| Janssen Biotech, Inc. | 16 | $315 |
| Lilly USA, LLC | 10 | $215 |
| Regeneron Healthcare Solutions, Inc. | 6 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $185 |
| Aimmune Therapeutics, Inc. | 9 | $176 |
| Ardelyx, Inc. | 5 | $111 |
| Ipsen Biopharmaceuticals, Inc | 4 | $101 |
| Gilead Sciences, Inc. | 5 | $97 |
Products named: XIFAXAN, TREMFYA, RINVOQ, CREON, OMVOH, DUPIXENT, ZENPEP, ENTYVIO.
Industry payments across MS — which companies pay providers there.
